- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
USV Launches USEMA - DCGI-Approved Injectable Semaglutide for Type 2 Diabetes - Video
|
Overview
USV Private Limited, a leading name in diabetes care, has announced the launch of USEMA, its semaglutide injection, for the management of Type 2 Diabetes Mellitus in India. With diabetes prevalence rising rapidly across the country, particularly among individuals with overweight and obesity, the introduction of USEMA aims to address a critical and growing healthcare need.
USEMA is available in two pen formats: a 2 mg pen delivering 0.25 mg and 0.5 mg doses, and a 4 mg pen delivering a 1 mg dose, offering flexibility in treatment based on patient requirements. Manufactured in India under stringent global quality standards, the product demonstrates proven bioequivalence, with similar efficacy, safety, and immunogenicity profiles as the reference innovator.
Developed through an integrated manufacturing process—from active pharmaceutical ingredient (API) to finished formulation—USEMA ensures consistency in quality, supported by robust cold-chain management.
Beyond treatment, USEMA is supported by a comprehensive patient care program designed to guide individuals through every stage of their diabetes journey. This initiative focuses on improving adherence, outcomes, and long-term health milestones.
With over six decades of experience, USV continues to strengthen its commitment to advancing diabetes care in India through innovation and patient-centric solutions.
Speakers
Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751


